サンプル依頼リスト カート
  • English
市場調査レポート
商品コード
1226899

中南米の肺動脈性肺高血圧症市場、2028年までの予測-地域別分析-薬剤別、タイプ別、投与経路別、流通チャネル別

South & Central America Pulmonary Arterial Hypertension Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - by Drugs, Type, Route of Administration, and Distribution Channel
出版日: | 発行: The Insight Partners | ページ情報: 英文 128 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
中南米の肺動脈性肺高血圧症市場、2028年までの予測-地域別分析-薬剤別、タイプ別、投与経路別、流通チャネル別
出版日: 2023年02月14日
発行: The Insight Partners
ページ情報: 英文 128 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

中南米の肺動脈性肺高血圧症市場は、2022年の7億3,227万米ドルから2028年には9億7,675万米ドルに成長すると予測され、2022年から2028年までのCAGRは4.9%と推定されています。

特許失効の拡大が、予測期間中の中南米の肺動脈性肺高血圧症市場の成長に有利な機会を提供

特許の失効により、ジェネリック医薬品が市場に参入し、製品ラインアップが多様化します。今後数年間で、いくつかの特許製品が特許切れとなることが予想され、ジェネリック製剤企業にとって大きなチャンスとなる可能性が高いです。finds Care Ratingsなど多くの製薬会社は、すでに特許製品のジェネリック版の開発に取り組んでいます。特許が切れた後、ジェネリック医薬品が利用できるようになります。消費者が低価格の恩恵を受ける一方で、特許保護を失うと、製薬会社は競争の激化にさらされることになります。したがって、特許失効は、ジェネリック医薬品メーカーが新たな市場に参入する機会を提供するものと期待されます。したがって、特許失効の拡大は、今後数年間、中南米の肺動脈性肺高血圧症市場の成長に有利な機会を提供することが期待されます。

中南米の肺動脈性肺高血圧症市場の概要

肺動脈性肺高血圧症（PAH）は、希少な進行性の疾患です。ブラジルの肺動脈性肺高血圧症」と題された調査によるものです：2020年12月に発表された「1次調査に基づく治療パターンと病院」では、参照先の公立病院でPAHを治療する6人の専門家を対象に調査が行われました。調査前の12カ月間に約1,045人の患者が医師によって治療されました。治療パターンと入院は、患者のリスク層別化によって分析されました。ほとんどの医師（67％）は、患者をリスク別に分類していました。低リスク群、中リスク群、高リスク群のそれぞれ47％、99％、74％で二重治療が、0％、1％、26％で三重治療が行われました。ヘルスケア資源の利用は、投薬や入院の必要性を考慮すると、肺動脈性肺高血圧症が進行した患者で多く、コストが56％高いことが示されました。さらに、ブラジルの登録では、肺動脈性肺高血圧症の最も一般的なサブタイプの1つとして、住血吸虫症が挙げられていました。非流行地域の紹介センターのデータによると、肺動脈性肺高血圧症患者の最大30％がスキストソミア症に関連している可能性があり、同国のPAH患者のスキストソミア症関連肺動脈性肺高血圧症（Sch-PAH）有病率が4.6％となっています。2021年に発表された研究「Basic and associated causes of schistosomiasis-related mortality in Brazil」によると、同国のPAH患者は治療に対するいくつかの障壁に直面しており、1999年から2018年の間に～4,168件のスキストソミア関連死が記録されました。さらに、1996年に設立されたSociedade Brasileira de Pneumologia e Tisiologia（SBPT、ブラジル胸部学会）肺循環委員会は、同国で長年にわたり、肺動脈性肺高血圧および慢性血栓塞栓性肺高血圧の管理に関する継続した教育とガイドライン/推奨事項の開発に関与しています。本委員会は、国内における肺動脈性肺高血圧症の治療に関する推奨事項のあらゆるアップデートを計画しています。2022年4月、記事にあるように、ブラジル国防省は肺動脈性肺高血圧症の患者を治療するために、部隊用のバイアグラ錠を発注しました。ブラジルでは、PAHaに特化した治療法は、ヘルスケア省が策定・公表する国家プロトコルによって規制されており、公的医療制度によって資金が提供されています。現在、ブラジルのSistema Unico de Saude（SUS、ブラジル統一医療制度）内では、PAHの治療薬として承認されているものはほとんどありません。同国で償還されるPAHa治療薬には、シルデナフィル、アンブリセンタン、ボセンタンがあります。その他のPAHa治療薬、例えばselexipagは、国内での使用が承認されていますが、国や地方政府から払い戻しは受けていません。したがって、上記の要因から、中南米の肺動脈性肺高血圧症市場は、予測期間中、同国で安定的に成長すると予想されます。

中南米の肺動脈性肺高血圧症市場の収益と2028年までの予測（億米ドル）

中南米の肺動脈性肺高血圧症市場のセグメント化

中南米の肺動脈性肺高血圧症市場は、薬剤、タイプ、投与経路、流通チャネル、国に基づいてセグメント化されます。

薬剤に基づき、中南米の肺動脈性肺高血圧症市場は、エンドセリン受容体拮抗薬（ERA）、プロスタサイクリンおよびプロスタサイクリン類似体、sGC刺激薬、pde-5 dipsticksに区分されます。2022年、プロスタサイクリンおよびプロスタサイクリンアナログセグメントは、中南米の肺動脈性肺高血圧症市場で最大のシェアを記録しました。

タイプに基づき、中南米の肺動脈性肺高血圧症市場は、ブランド品とジェネリック医薬品に二分されます。2022年、中南米の肺動脈性肺高血圧症市場では、ブランド品がより大きなシェアを記録しました。

投与経路に基づき、中南米の肺動脈性肺高血圧症市場は、経口、静脈内/皮下、吸入に区分されます。2022年、中南米の肺動脈性肺高血圧症市場では、経口投与セグメントが最大のシェアを記録しました。

流通チャネルに基づき、中南米の肺動脈性肺高血圧症市場は、病院薬局・クリニック、オンライン薬局、小売薬局に区分されます。2022年には、病院薬局・クリニックセグメントが中南米の肺動脈性肺高血圧症市場で最大のシェアを記録しました。

国別に見ると、中南米の肺動脈性肺高血圧症市場は、ブラジル、アルゼンチン、その他中南米に区分されます。2022年、ブラジルは中南米の肺動脈性肺高血圧症市場で最大のシェアを記録しました。

Bayer AG、Gilead Sciences Inc、GSK Plc、Johnson &Johnson、Lupin Ltd、Novartis AG、Pfizer Inc、Teva Pharmaceutical Industries Ltdは、中南米の肺動脈性肺高血圧症市場で活動している主要企業です。

目次

第1章 イントロダクション

第2章 中南米の肺動脈性肺高血圧症市場- 主要な要点

第3章 調査手法

  • カバレッジ
  • 2次調査
  • 1次調査

第4章 中南米の肺動脈性肺高血圧症市場- 市場情勢

  • 中南米のPEST分析
  • 専門家別オピニオン

第5章 中南米の肺動脈性肺高血圧症市場-主要市場力学

  • 市場促進要因
    • 肺動脈性肺高血圧症の罹患率の増加
  • 市場抑制要因
    • 肺動脈性肺高血圧症の治療に使用される薬剤の副作用
  • 市場機会
    • 特許切れ別ジェネリック医薬品の入手の困難化
  • 今後の動向
    • 肺動脈性肺高血圧症の治療薬開発のための臨床試験の増加
  • 影響度分析

第6章 肺動脈性肺高血圧症市場-中南米分析

  • 中南米の肺動脈性肺高血圧症市場の収益予測と分析

第7章 中南米の肺動脈性肺高血圧症市場-2028年までの収益と予測：薬剤別

  • 中南米の肺動脈性肺高血圧症市場収入シェア：薬剤別、 2021年・2028年（%）
  • エンドセリン受容体拮抗薬（ERAs）
  • プロスタサイクリンおよびプロスタサイクリンアナログ
  • SGC刺激剤
  • Pde-5ディップスティック

第8章 中南米の肺動脈性肺高血圧症の市場分析と2028年までの予測：タイプ別

  • 中南米の肺動脈性肺高血圧症市場：タイプ別2021年・2028年（%）
  • ブランド品
  • ジェネリック医薬品

第9章 中南米の肺動脈性肺高血圧症市場-2028年までの収益と予測-投与経路別

  • 中南米の肺動脈性肺高血圧症市場収入シェア：投与経路別2021年・2028年（%）
  • 経口
  • 静脈内/皮下
  • 吸入投与

第10章 中南米の肺動脈性肺高血圧症市場-2028年までの収益と予測：流通チャネル別

  • 中南米の肺動脈性肺高血圧症市場売上高シェア：流通チャネル別2021年・2028年（%）
  • 病院の薬局・診療所
  • オンライン薬局
  • 小売薬局

第11章 中南米の肺動脈性肺高血圧症市場-2028年までの収益と予測：国別分析

    • 中南米
      • ブラジル
      • アルゼンチン
      • その他中南米諸国

第12章 中南米の肺動脈性肺高血圧症市場- 業界情勢

  • 有機的な展開
  • 無機的な開発

第13章 企業プロファイル

  • Johnson & Johnson
  • Gilead Sciences Inc
  • Bayer AG
  • Novartis AG
  • GSK Plc
  • Teva Pharmaceutical Industries Ltd
  • Lupin Ltd
  • Pfizer Inc

第14章 付録

図表

List Of Tables

  • Table 1. SAM: Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 2. Brazil: Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
  • Table 3. Brazil: Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 4. Brazil: Pulmonary Arterial Hypertension Market, by Route of Administration- Revenue and Forecast to 2028 (US$ Million)
  • Table 5. Brazil: Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
  • Table 6. Argentina: Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
  • Table 7. Argentina: Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 8. Argentina: Pulmonary Arterial Hypertension Market, by Route of Administration- Revenue and Forecast to 2028 (US$ Million)
  • Table 9. Argentina: Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
  • Table 10. Rest of SAM: Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
  • Table 11. Rest of SAM: Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 12. Rest of SAM: Pulmonary Arterial Hypertension Market, by Route of Administration- Revenue and Forecast to 2028 (US$ Million)
  • Table 13. Rest of SAM: Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
  • Table 14. Organic Developments in the SAM pulmonary arterial hypertension market
  • Table 15. Inorganic Developments in the SAM pulmonary arterial hypertension market
  • Table 16. Glossary of Terms

List Of Figures

  • Figure 1. SAM Pulmonary Arterial Hypertension Market Segmentation
  • Figure 2. SAM Pulmonary Arterial Hypertension Market - By Country
  • Figure 3. SAM Pulmonary Arterial Hypertension Market Overview
  • Figure 4. Prostacyclin and Prostacyclin Analogs Segment Held Largest Share by Drugs of the SAM Pulmonary Arterial Hypertension Market
  • Figure 5. Brazil to Show Significant Growth During Forecast Period
  • Figure 6. SAM: PEST Analysis
  • Figure 7. Experts Opinion
  • Figure 8. SAM Pulmonary Arterial Hypertension Market Impact Analysis of Drivers and Restraint
  • Figure 9. SAM Pulmonary Arterial Hypertension Market- Revenue Forecast and Analysis - 2020 - 2028
  • Figure 10. SAM Pulmonary Arterial Hypertension Market Revenue Share, by Drugs 2021 & 2028 (%)
  • Figure 11. Endothelin Receptor Antagonists (ERAs): SAM Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 12. Prostacyclin and Prostacyclin Analogs: SAM Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 13. sGC Stimulators: SAM Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 14. Pde-5 Dipsticks: SAM Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 15. SAM Pulmonary Arterial Hypertension Market, by Type 2021 & 2028 (%)
  • Figure 16. Branded: SAM Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 17. Generics: SAM Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 18. SAM Pulmonary Arterial Hypertension Market Revenue Share, by Route of Administration 2021 & 2028 (%)
  • Figure 19. Oral: SAM Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 20. Intravenous/ Subcutaneous: SAM Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 21. Inhalational: SAM Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 22. SAM Pulmonary Arterial Hypertension Market Revenue Share, by Distribution Channel 2021 & 2028 (%)
  • Figure 23. Hospital Pharmacies and Clinics: SAM Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 24. Online Pharmacies: SAM Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 25. Retail Pharmacies: SAM Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 26. South & Central America: Pulmonary Arterial Hypertension Market, by Key Country - Revenue (2021) (US$ Million)
  • Figure 27. South & Central America: Pulmonary Arterial Hypertension Market, by Country, 2021 & 2028 (%)
  • Figure 28. Brazil: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 29. Argentina: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 30. Rest of SAM: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
目次
Product Code: BMIRE00028073

The South & Central America pulmonary arterial hypertension market is expected to grow from US$ 732.27 million in 2022 to US$ 976.75 million by 2028; it is estimated to grow at a CAGR of 4.9% from 2022 to 2028.

Growing Patent Expiration to Offer Lucrative Opportunities for South & Central America Pulmonary Arterial Hypertension Market Growth During Forecast Period

Patent expiry permits generic drugs to enter the market and diversify product offerings. A few patented products are expected to become off-patent in the coming years, which is likely to provide an enormous opportunity for generic formulation companies. Many pharma companies such as finds Care Ratings are already working to develop the generic version of patented products. After patent expiration, generic versions of drugs can become available. While consumers benefit from low prices, losing patent protection can expose pharmaceutical companies to growing competition. Thus, patent expiration is expected to offer an opportunity for generic drug manufacturers to enter a new market. Hence, the growing patent expiration is expected to offer lucrative opportunities for the South & Central America pulmonary arterial hypertension market growth in the coming years.

South & Central America Pulmonary Arterial Hypertension Market Overview

Pulmonary arterial hypertension (PAH) is a rare, progressive disease. As per a study titled "Pulmonary Arterial Hypertension in Brazil: Treatment Patterns and Hospitalization Based on Primary Research," published in December 2020, a survey was conducted with six experts in treating PAH in referential public hospitals. Approximately 1,045 patients were treated by the physicians in the 12 months prior to the survey. Treatment patterns and hospitalization were analyzed by patient's risk stratification. Most physicians (67%) stratified patients by risk. Double therapy was used in 47%, 99%, and 74%, and triple therapy at 0%, 1%, and 26% of the patients in low-risk, intermediate-risk, and high-risk groups, respectively. Healthcare resource utilization was greater in patients with progressed pulmonary arterial hypertension, considering medication or hospitalization needs, indicating that costs were 56% higher. Moreover, schistosomiasis was mentioned as one of the most common subtypes of pulmonary arterial hypertension by the Brazilian registry. Data from referral centers in nonendemic regions indicate that up to 30% of pulmonary arterial hypertension cases may be related to schistosomiasis, with a prevalence of schistosomiasis-associated pulmonary arterial hypertension (Sch-PAH) in 4.6% of PAH patients in the country. According to the study "Basic and associated causes of schistosomiasis-related mortality in Brazil," published in 2021, ~4,168 schistosomiasis-related deaths were recorded between 1999 and 2018, as patients with PAH in the country face several barriers to treatment. Further, the Sociedade Brasileira de Pneumologia e Tisiologia (SBPT, Brazilian Thoracic Association) Pulmonary Circulation Committee, founded in 1996, has been involved in continued education and development of guidelines/recommendations for the management of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension over the years in the country. This committee plans any update on the recommendations for the treatment of pulmonary arterial hypertension in the country. In April 2022, as per an article, the Brazilian defense ministry ordered Viagra pills for troops to treat patients with pulmonary arterial hypertension. In Brazil, PAHa specific therapies are regulated by a national protocol, formed and published by the Ministry of Health, and funded by the public healthcare system. Currently, few drugs are approved for treating PAH within the Sistema Unico de Saude (SUS, Brazilian Unified Health Care System) in Brazil. The PAHa specific drugs reimbursed in the country include sildenafil, ambrisentan, and bosentan. Other PAHa specific drugs, such as selexipag, are approved for usage within the country but are not reimbursed by the national or local government. Thus, as per the above-mentioned factors, the South & Central America pulmonary arterial hypertension market is expected to grow steadily in the country during the forecast period.

South & Central America Pulmonary Arterial Hypertension Market Revenue and Forecast to 2028 (US$ Billion)

South & Central America Pulmonary Arterial Hypertension Market Segmentation

The South & Central America pulmonary arterial hypertension market is segmented on the basis of drugs, type, route of administration, distribution channel, and country.

Based on drugs, the South & Central America pulmonary arterial hypertension market is segmented into endothelin receptor antagonists (ERAs), prostacyclin and prostacyclin analogs, sGC stimulators, and pde-5 dipsticks. In 2022, the prostacyclin and prostacyclin analogs segment registered the largest share in the South & Central America pulmonary arterial hypertension market.

Based on type, the South & Central America pulmonary arterial hypertension market is bifurcated into branded and generics. In 2022, the branded segment registered a larger share in the South & Central America pulmonary arterial hypertension market.

Based on route of administration, the South & Central America pulmonary arterial hypertension market is segmented into oral, intravenous/subcutaneous, and inhalational. In 2022, the oral segment registered the largest share in the South & Central America pulmonary arterial hypertension market.

Based on distribution channel, the South & Central America pulmonary arterial hypertension market is segmented into hospital pharmacies and clinics, online pharmacies, and retail pharmacies. In 2022, the hospital pharmacies and clinics segment registered the largest share in the South & Central America pulmonary arterial hypertension market.

Based on country, the South & Central America pulmonary arterial hypertension market is segmented into Brazil, Argentina, and the Rest of South & Central America. In 2022, Brazil registered the largest share in the South & Central America pulmonary arterial hypertension market.

Bayer AG, Gilead Sciences Inc, GSK Plc, Johnson & Johnson, Lupin Ltd, Novartis AG, Pfizer Inc, and Teva Pharmaceutical Industries Ltd are the leading companies operating in the South & Central America pulmonary arterial hypertension market.

Reasons to Buy:

  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the South & Central America pulmonary arterial hypertension market.
  • Highlights key business priorities in order to assist companies to realign their business strategies
  • The key findings and recommendations highlight crucial progressive industry trends in the South & Central America pulmonary arterial hypertension market, thereby allowing players across the value chain to develop effective long-term strategies
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
  • Scrutinize in-depth South & Central America market trends and outlook coupled with the factors driving the pulmonary arterial hypertension market, as well as those hindering it
  • Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 The Insight Partners Research Report Guidance
  • 1.3 Market Segmentation
    • 1.3.1 SAM Pulmonary Arterial Hypertension Market - By Drugs
    • 1.3.2 SAM Pulmonary Arterial Hypertension Market - By Type
    • 1.3.3 SAM Pulmonary Arterial Hypertension Market - By Route of Administration
    • 1.3.4 SAM Pulmonary Arterial Hypertension Market - By Distribution Channel
    • 1.3.5 SAM Pulmonary Arterial Hypertension Market - By Country

2. SAM Pulmonary Arterial Hypertension Market - Key Takeaways

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. SAM Pulmonary Arterial Hypertension Market - Market Landscape

  • 4.1 Overview
  • 4.2 SAM PEST Analysis
  • 4.3 Experts Opinion

5. SAM Pulmonary Arterial Hypertension Market - Key Market Dynamics

  • 5.1 Market Drivers
    • 5.1.1 Growing Incidence of Pulmonary Arterial Hypertension
  • 5.2 Market Restraints
    • 5.2.1 Side Effects of Drugs Used for Treatment of Pulmonary Arterial Hypertension
  • 5.3 Market Opportunities
    • 5.3.1 Availability of Generics at Affordable Costs Due to Growing Patent Expiration
  • 5.4 Future Trend
    • 5.4.1 Rising Clinical Trials for Drugs Development to Treat Pulmonary Arterial Hypertension
  • 5.5 Impact analysis

6. Pulmonary Arterial Hypertension Market - SAM Analysis

  • 6.1 SAM Pulmonary Arterial Hypertension Market Revenue Forecast and Analysis

7. SAM Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 - by Drugs

  • 7.1 Overview
  • 7.2 SAM Pulmonary Arterial Hypertension Market Revenue Share, by Drugs 2021 & 2028 (%)
  • 7.3 Endothelin Receptor Antagonists (ERAs)
    • 7.3.1 Overview
    • 7.3.2 Endothelin Receptor Antagonists (ERAs): SAM Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.4 Prostacyclin and Prostacyclin Analogs
    • 7.4.1 Overview
    • 7.4.2 Prostacyclin and Prostacyclin Analogs: SAM Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.5 SGC Stimulators
    • 7.5.1 Overview
    • 7.5.2 sGC Stimulators: SAM Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.6 Pde-5 Dipsticks
    • 7.6.1 Overview
    • 7.6.2 Pde-5 Dipsticks: SAM Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)

8. SAM Pulmonary Arterial Hypertension Market Analysis and Forecasts to 2028 - by Type

  • 8.1 Overview
  • 8.2 SAM Pulmonary Arterial Hypertension Market, by Type 2021 & 2028 (%)
  • 8.3 Branded
    • 8.3.1 Overview
    • 8.3.2 Branded: SAM Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • 8.4 Generics
    • 8.4.1 Overview
    • 8.4.2 Generics: SAM Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)

9. SAM Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 - by Route of Administration

  • 9.1 Overview
  • 9.2 SAM Pulmonary Arterial Hypertension Market Revenue Share, by Route of Administration 2021 & 2028 (%)
  • 9.3 Oral
    • 9.3.1 Overview
    • 9.3.2 Oral: SAM Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • 9.4 Intravenous/ Subcutaneous
    • 9.4.1 Overview
    • 9.4.2 Intravenous/ Subcutaneous: SAM Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • 9.5 Inhalational
    • 9.5.1 Overview
    • 9.5.2 Inhalational: SAM Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)

10. SAM Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 - by Distribution Channel

  • 10.1 Overview
  • 10.2 SAM Pulmonary Arterial Hypertension Market Revenue Share, by Distribution Channel 2021 & 2028 (%)
  • 10.3 Hospital Pharmacies and Clinics
    • 10.3.1 Overview
    • 10.3.2 Hospital Pharmacies and Clinics: SAM Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • 10.4 Online Pharmacies
    • 10.4.1 Overview
    • 10.4.2 Online Pharmacies: SAM Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • 10.5 Retail Pharmacies
    • 10.5.1 Overview
    • 10.5.2 Retail Pharmacies: SAM Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)

11. SAM Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 - Country Analysis

  • 11.1 Overview
    • 11.1.2 South & Central America: Pulmonary Arterial Hypertension Market, by Country, 2021 & 2028 (%)
      • 11.1.2.1 Brazil: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.1.2.1.1 Overview
        • 11.1.2.1.2 Brazil: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.1.2.1.3 Brazil: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
        • 11.1.2.1.4 Brazil: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
        • 11.1.2.1.5 Brazil: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
        • 11.1.2.1.6 Brazil: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
      • 11.1.2.2 Argentina: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.1.2.2.1 Overview
        • 11.1.2.2.2 Argentina: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.1.2.2.3 Argentina: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
        • 11.1.2.2.4 Argentina: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
        • 11.1.2.2.5 Argentina: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
        • 11.1.2.2.6 Argentina: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
      • 11.1.2.3 Rest of SAM: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.1.2.3.1 Overview
        • 11.1.2.3.2 Rest of SAM: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.1.2.3.3 Rest of SAM: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
        • 11.1.2.3.4 Rest of SAM: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
        • 11.1.2.3.5 Rest of SAM: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
        • 11.1.2.3.6 Rest of SAM: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)

12. SAM Pulmonary Arterial Hypertension Market - Industry Landscape

  • 12.1 Overview
  • 12.2 Organic Developments
    • 12.2.1 Overview
  • 12.3 Inorganic Developments
    • 12.3.1 Overview

13. Company Profiles

  • 13.1 Johnson & Johnson
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Products and Services
    • 13.1.4 Financial Overview
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments
  • 13.2 Gilead Sciences Inc
    • 13.2.1 Key Facts
    • 13.2.2 Business Description
    • 13.2.3 Products and Services
    • 13.2.4 Financial Overview
    • 13.2.5 SWOT Analysis
    • 13.2.6 Key Developments
  • 13.3 Bayer AG
    • 13.3.1 Key Facts
    • 13.3.2 Business Description
    • 13.3.3 Products and Services
    • 13.3.4 Financial Overview
    • 13.3.5 SWOT Analysis
    • 13.3.6 Key Developments
  • 13.4 Novartis AG
    • 13.4.1 Key Facts
    • 13.4.2 Business Description
    • 13.4.3 Products and Services
    • 13.4.4 Financial Overview
    • 13.4.5 SWOT Analysis
    • 13.4.6 Key Developments
  • 13.5 GSK Plc
    • 13.5.1 Key Facts
    • 13.5.2 Business Description
    • 13.5.3 Products and Services
    • 13.5.4 Financial Overview
    • 13.5.5 SWOT Analysis
    • 13.5.6 Key Developments
  • 13.6 Teva Pharmaceutical Industries Ltd
    • 13.6.1 Key Facts
    • 13.6.2 Business Description
    • 13.6.3 Products and Services
    • 13.6.4 Financial Overview
    • 13.6.5 SWOT Analysis
    • 13.6.6 Key Developments
  • 13.7 Lupin Ltd
    • 13.7.1 Key Facts
    • 13.7.2 Business Description
    • 13.7.3 Products and Services
    • 13.7.4 Financial Overview
    • 13.7.5 SWOT Analysis
    • 13.7.6 Key Developments
  • 13.8 Pfizer Inc
    • 13.8.1 Key Facts
    • 13.8.2 Business Description
    • 13.8.3 Products and Services
    • 13.8.4 Financial Overview
    • 13.8.5 SWOT Analysis
    • 13.8.6 Key Developments

14. Appendix

  • 14.1 About The Insight Partners
  • 14.2 Glossary of Terms